IDT Biologika to provide live virus filling and finishing services to BARDA

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Remains)
(Image: iStock/Remains)

Related tags Immune system Molecule

IDT Biologika has been awarded a five-year contract to provide live virus filling and finishing services in a deal worth up to $50m.

The award comes from the Biomedical Advanced Research and Development Authority (BARDA) and includes an initial commitment of $100,000, subject to task orders for a maximum amount of $50m.

Per the contract, IDT Biologika will provide services to support cGMP and non-GMP filling and finishing of a variety of medical countermeasure​ products, which the organization uses for stockpiling and response through several different initiatives. 

Read: BARDA talks medical countermeasure manufacturing

According to IDT, the company will support live virus/vectored vaccine fill finish and potentially for small molecule injectables, large molecule sterile injectables, monoclonal antibodies, and other development-stage and FDA-approved medical countermeasures.

As a second part of the contract, IDT will also provide rapid response readiness for medical countermeasures within an accelerated time frame.

Jose Ochoa, Chief Business Officer at IDT Biologika told us the company doesn’t have any plans currently to increase capacity.

We can meet the expected contract requirements with existing capacity using a combination of resources​,” he said, referencing the company’s facility in Germany and the US.

What facilities will be used, one or both, will depend on the government's need in terms of volume and speed, Ochoa explained.

US-based contract manufacturing

IDT recently celebrated​ its first year of operations in the United States, after opening its doors last September​ in Rockville, Maryland.

As previously reported​, the site’s production infrastructure has been upgraded for clinical Phase I and Phase II vaccine and viral vector projects.

The company has also added several new capabilities during the past year and is in the process of an expansion that will introduce quality upgrades.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more